However, SETD7 inhibition could enhance EMT, dedifferentiation and proliferation because its activity is necessary for the Hippo pathway and activation of tumor suppressors, including pRb; thus, use of SETD7 inhibitors would not be advisable in tumors that are dependent on EGF for growth (many of which are triple negative). This evidence concerns the gene SETD7 and neoplasm.